Table 3 Predictors of SF-36 component 12 weeks after DAA treatment

Male gender

1.05 (0.43–2.58)

1.000

3.14 (1.12–8.80)

0.005

6.21 (1.69–22.88)

1.79 (0.85–3.75)

0.111

2.78 (0.91–8.46)

2.07 (0.73–5.87)

0.37 (0.10–1.38)

Age ≤ 40 year

0.72 (0.42–1.26)

0.356

0.91 (0.67–1.25)

0.695

1.12 (0.79–1.60)

0.627

1.07 (0.66–1.73)

University education

1.03 (0.59–1.77)

1,000

0.96 (0.71–1.29)

0.901

0.95 (0.70–1.30)

0.871

0.83 (0.53–1.29)

Married versus not married

1.56 (0.63–3.88)

0.574

1.05 (0.49–2.27)

0.648

0.57 (0.26–1.25)

0.351

1.59 (0.71–3.57)

1.74 (0.75–4.01)

Married versus Widow/divorce

1.42 (0.47–4.26)

0.574

1.56 (0.61–4.00)

0.648

0.98 (0.38–2.50)

0.351

2.50 (0.84–7.40)

2.27 (0.75–6.90)

Regular worker versus non-regular

1.76 (0.78–3.96)

0.356

0.90 (0.44–1.85)

0.020

1.08 (0.50–2.35)

1.26 (0.62–2.56)

0.380

0.97 (0.47–2.02)

Regular worker versus not working

1.42 (0.47–4.26)

0.356

3.69 (1.27–10.71)

0.020

2.52 (0.76–8.39)

2.00 (0.74–7.37)

0.380

1.26 (0.45–3.56)

CD4 > 500 versus 350–500

1.06 (0.36–3.10)

0.957

0.60 (0.23–1.55)

0.676

0.84 (0.33–2.12)

0.914

0.62 (0.24–1.60)

0.55 (0.20–1.50)

CD4 > 500 versus < 350

0.86 (0.36–2.06)

0.957

0.84 (0.39–1.83)

0.676

0.84 (0.39–1.83)

0.914

0.62 (0.28–1.37)

0.55 (0.23–1.29)

HCV-RNA > 800,000 IU/mL

0.99 (0.52–1.88)

1,000

0.97 (0.69–1.37)

1,000

0.94 (0.66–1.32)

0.861

0.78 (0.49–1.23)

Interferon failure

0.56 (0.15–2.08)

0.515

0.99 (0.58–1.67)

1,000

1.02 (0.60–1.72)

1,000

1.81 (1.11–2.95)

3.09 (0.96–10.01)

Achieving SVR12

0.91 (0.27–3.05)

1,000

0.75 (0.46–1.23)

0.455

1.90 (0.58–6.20)

0.253

0.85 (0.35–2.05)

Non-smoker

1.01 (0.59–1.75)

1,000

0.89 (0.66–1.20)

0.564

0.89 (0.66–1.21)

0.564

1.05 (0.69–1.62)

BMI normal versus underweight

1.20 (0.40–3.64)

0.659

0.66 (0.24–1.80)

0.437

0.60 (0.22–1.65)

0.440

0.40 (0.15–1.08)

0.45 (0.16–1.28)

BMI normal versus overweight/obese

1.54 (0.60–3.98)

0.659

1.37 (0.62–3.02)

0.437

1.26 (0.57–2.77)

0.440

0.90 (0.39–2.06)

0.68 (0.27–1.69)

Non-IVDU

1.22 (0.56–2.68)

0.763

0.32 (0.11–0.89)

0.005

0.27 (0.07–1.13)

0.94 (0.56–1.57)

1,000

1.23 (0.67–2.24)

Fibrosis stage F0–F1 versus F2–F3

1.00 (0.37–2.66)

0.276

1.28 (0.55–2.94)

0.243

1.69 (0.70–4.08)

1,20 (0.52–2.75)

0.298

0.76 (0.32–1.80)

Fibrosis stage F0–F1 versus F4

0.50 (0.20–1.22)

0.276

2.06 (0.88–4.85)

0.243

2.85 (1.16–7.00)

0.55 (0.23–1.32)

0.298

0.72 (0.30–1.71)

Non-anemia

0.58 (0.33–1.04)

0.141

0.46 (0.19–1.13)

1.16 (0.75–1.80)

0.621

1,40 (0.84–2,32)

0.221

1.68 (0.68–4.12)

1.63 (0.79–3.39)

1.52 (0.52–4.56)

NNRTI-based versus PI-based ART

1.76 (0.60–5.16)

0.402

1.17 (0.71–1.93)

0.674

1.14 (0.69–1.88)

0.771

1.85 (0.75–4.53)

2.47 (0.76–8.00)